Heterozygous familial hypercholesterolemia drug market is anticipated to grow at a significant CAGR during the forecast period. Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder. It causes high cholesterol levels that lead to heart disease, heart attack, or stroke. Additionally, HeFH is one form of Familial Hypercholesterolemia (FH). The major factor driving the demand for the heterozygous familial hypercholesterolemia drug is the increasing prevalence of familial hypercholesterolemia across the globe.
According to Medline Plus, familial hypercholesterolemia affects an estimated 1 in 200 to 1 in 250 people in most countries. Additionally, it is the most common inherited condition affecting the heart and blood vessels. Furthermore, the condition occurs more frequently in certain populations that include Afrikaners in South Africa, Lebanese, and Tunisians. Hence, the increasing prevalence of familial hypercholesterolemia is driving the demand for heterozygous familial hypercholesterolemia drugs for treatment which in turn is driving the growth of the market.
Some major players in the market include Sanofi SA, Amgen Inc., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, Amgen announced the approval of Repatha (evolocumab) from the US Food and Drug Administration (FDA). It is used as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 10 years and older.
To Request a Sample of our Report on Heterozygous Familial Hypercholesterolemia Drug Market: https://www.omrglobal.com/request-sample/heterozygous-familial-hypercholesterolemia-drug-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Product Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Sanofi SA, Amgen Inc., and Novartis International AG, among others.
Heterozygous Familial Hypercholesterolemia Drug Market Report by Segment
By Type
- Gemcabene Calcium
- MGL-3196
- ST-103
- Others
By Application
- Hospital
- Medical Center
- Clinics
- Others
A full Report of Heterozygous Familial Hypercholesterolemia Drug Market is Available @ https://www.omrglobal.com/industry-reports/heterozygous-familial-hypercholesterolemia-drug-market
Heterozygous Familial Hypercholesterolemia Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
